This session will focus on the management of non-alcoholic fatty liver disease (NAFLD) with a particular emphasis on the role of GLP-1 agonists and SGLT-2 inhibitors in treating this condition.
|
The gut microbiome is recognized as an important factor in obesity. This webinar will review the interconnection between obesity and the gut microbiome.
|
Obesity is emerging as a serious and complex health condition affecting about 1 billion people in the world.
|
Insulin resistance (IR) is a common biochemical abnormality in patients with excess adiposity, obesity, and its complications.
|
|
Pages
- « first
- ‹ previous
- 1
- 2
- 3